Annual report pursuant to Section 13 and 15(d)

Revenue - Revenue from contracts with customers (Details)

v3.22.0.1
Revenue - Revenue from contracts with customers (Details)
1 Months Ended 12 Months Ended
Jan. 01, 2021
USD ($)
Jan. 13, 2020
USD ($)
Oct. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
contract
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Revenue            
Revenue       $ 6,149,000 $ 3,958,000 $ 1,122,000
Number of contracts with customers | contract       3    
Increase in deferred revenue $ 147,330,000     $ 149,785,000 47,973,000 2,095,000
Deferred revenue $ 52,092,000     199,422,000    
Development revenue            
Revenue            
Revenue       6,149,000 3,958,000 $ 1,122,000
GSK Collaboration And License Agreement            
Revenue            
Upfront payment received     $ 150,000,000      
Astellas Collaboration Agreement            
Revenue            
Upfront payment received   $ 50,000,000        
Astellas Collaboration Agreement | GlaxoSmithKline Intellectual Property Development Ltd            
Revenue            
Deferred revenue         $ 52,092,000  
Revenue recognized in the period       $ 1,498,000